### REVIEW



# Vitamin D receptor gene polymorphisms and multiple myeloma: a meta-analysis

Chunyi Lyu $^1 \cdot$  Xuewei Yin $^1 \cdot$  Zonghong Li $^1 \cdot$  Teng Wang $^1 \cdot$  Ruirong Xu $^{2,3}$ 

Received: 19 June 2023 / Accepted: 18 May 2024 / Published online: 4 June 2024 © The Author(s) 2024

## Abstract

Vitamin D acts through the vitamin D receptor (VDR), and vitamin D level decreases in multiple myeloma (MM) patients. Single nucleotide polymorphisms in VDR alter its functions to affect the vitamin D status. This raises the question of whether VDR gene polymorphisms are associated with MM risk, which has been investigated in case-control studies, but the results have been inconsistent. This meta-analysis aimed to investigate the relationship between VDR gene polymorphisms and MM risk. The PubMed, Web of Science, Medline, Embase, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal (VIP), Wanfang Databases (WANFANG) were searched from inception to June 1, 2023, without language restriction or publication preference. Pooled odds ratio (OR) and 95% confidence interval (CI) for each variable were calculated. Leave-one-out sensitivity analysis was performed to determine the source of heterogeneity. Publication bias was assessed using Begg' and Egger's tests, and the trim-and-fill method was used to compensate for publication bias. The correlation meta-analysis was conducted using Comprehensive Meta-Analysis 3.0 and STATA 12.0 software. All the included studies were based on Asian populations and involved four VDR gene polymorphisms, TaqI (rs731236), ApaI (rs7975232), BsmI (rs1544410) and FokI (rs2228570). The results showed that TaqI (C vs. T: OR = 1.487, 95% CI 1.052, 2.104, P = 0.025; CC+CT vs. TT: OR = 1.830, 95% CI 1.138, 2.944, P=0.013), ApaI (T vs. G: OR = 1.292, 95% CI 1.101, 1.517, P=0.002; TT vs. GG: OR = 1.600, 95% CI 1.106, 2.314, P = 0.013; TG vs. GG: OR 1.305, 95% CI 1.050, 1.622; P = 0.016; TT + TG vs. GG: OR = 1.353, 95% CI 1.103, 1.662, P = 0.004), BsmI (GG vs. AA: OR = 1.918, 95% CI 1.293, 2.844, P = 0.001; GA vs. AA: OR = 1.333, 95% CI 1.058, 1.679, P = 0.015; G vs. A: OR = 1.398, 95% CI 1.180, 1.657, P = 0.000; GG vs. AA + GA: OR = 1.686, 95% CI 1.174, 2.423, P = 0.005), and FokI (T vs. C: OR = 1.687, 95% CI 1.474, 1.931, P = 0.000; TT vs. CC: OR = 2.829, 95% CI 2.066, 3.872, P = 0.000; TC vs. CC: OR = 1.579, 95% CI 1.304, 1.913, P = 0.000, TT + TC vs. CC: OR = 1.771, 95% CI 1.477, 2.125, P = 0.000; TT vs. CC + TC: OR = 2.409, 95% CI 1.814, 3.200, P = 0.000) are associated with MM risk. VDR gene polymorphisms including ApaI, BsmI, TaqI, and FokI are associated with MM risk in Asian populations. Additional studies with large sample sizes and different ethnicities are needed.

Keyword Multiple myeloma · Gene polymorphism · Vitamin D receptor · Meta-analysis

*Key message* VDR gene polymorphisms (ApaI, BsmI, TaqI, and FokI) are associated with MM risk in individuals of Asian ethnicity.

Ruirong Xu shandongxuruirong@163.com

- <sup>1</sup> Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China
- <sup>2</sup> Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China
- <sup>3</sup> Shandong Key Laboratory of Hematology of Integrated Traditional Chinese and Western Medicine of Health Commission, Institute of Hematology, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China

# Introduction

Multiple myeloma (MM) is a malignancy of clonal plasma cells that manifests clinically as bone pain, pathologic fractures, anemia, and renal insufficiency [1]. An increasing number of studies have reported that patients newly diagnosed with MM have low levels of vitamin D [2], and vitamin D deficiency is correlated with myeloma activity [3], the occurrence of peripheral neuropathy (PN) [4, 5], and poorer outcomes [6]. Evidence from laboratory has shown that analogs of vitamin D inhibit the growth of the myeloma cell line NCI-H929 via cell cycle arrest and apoptosis [7–11], and

vitamin D supplements have potential for improving cancer prognosis and outcome in deficient individuals [12].

Vitamin D functions through its vitamin D receptor (VDR), and genetic variations of VDR could influence an individual's vitamin D status [13, 14]. Polymorphisms caused by single nucleotides at the genome level are described as single nucleotide polymorphisms (SNPs), the most common form of variations among individuals. The most reported VDR gene polymorphisms are the BsmI (rs1544410), FokI (rs2228570), TaqI (rs731236) and ApaI (rs7975232) [15]. Studies have explored the association between these VDR gene polymorphisms and cancer development, and revealed that BsmI is associated with overall survival in patients with cancer, that ApaI is associated with progression-free survival in patients with cancer, and that FokI is associated with overall survival in patients with lung cancer [16]. In this study, we hypothesized that VDR gene polymorphisms could affect the binding of the VDR and have the potential to influence the risk of MM. MM is a multifactorial disease involving genetics [17], and factors such as the lifestyle and environmental exposures might change the actual effect of SNPs. Additionally, there is genetic heterogeneity in different ethnic populations [18]. These are uncertainties and conflicts that underlie the hypotheticals.

In MM, VDR gene polymorphisms have been investigated in several case-control studies [19-24], and a meta-analysis indicated that the heterozygote and homozygote models of FokI and the homozygote model of ApaI are associated with an increased risk of MM [18]. However, conflicting conclusions have been reported in case-control studies, and the associations of BsmI and TaqI with MM were not explored in previous meta-analysis. Further, significant heterogeneity was observed in the existing meta-analysis. In this study, we focused on the following clinical question: Is there an association between VDR gene polymorphisms and the risk of MM? This evidence will indicate the existence of VDR gene polymorphisms that may increase genetic susceptibility to MM in healthy individuals to promote earlier screening and diagnosis, and will provide evidence for developing therapies against VDR gene polymorphisms for MM patients. Therefore, a meta-analysis was conducted with the aim of examining and summarizing the evidence on the association between VDR gene polymorphisms and MM risk.

# Materials and methods

## Ethics

This study did not require patient recruitment or personal data collection, and there was no need for ethics committee approval.

#### **Protocol registration**

This meta-analysis was conducted following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist [25] and Cochrane Handbook criteria, and the protocol was registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) with registration number INPLASY202330076. The PRISMA 2020 checklist is provided in Supplementary file 1.

### **Eligibility criteria and study selection**

The research question was formulated using Population, Intervention, Comparison, Outcomes, and Study (PICOS) guidelines [26]. In the PICOS form, the studies were described as follows: P, patients diagnosed with MM; I, VDR gene polymorphisms; C, healthy control groups; O, effect of VDR gene polymorphisms associated with MM risk; S, case-control study. The inclusion criteria were as follows: (i) case-control study in humans in which the association between VDR polymorphisms and MM risk was investigated; (ii) the case group included patients who meet the diagnostic criteria for MM, and the control group included healthy individuals; (iii) the number of individuals with each genotype in the case and control groups was sufficient to calculate odds ratio (OR) and 95% confidence interval (95% CI); and (iv) the genotype distributions of the control group followed the Hardy-Weinberg equilibrium (HWE). The exclusion criteria were as follows: (i) not a case-control study reporting the association between VDR gene polymorphisms and MM risk; (ii) studies containing data repeated from another published study; (iii) studies containing incomplete data or data that could not be analyzed; (iv) studies with missing or apparently incorrect data; and (v) reviews, case reports, or basic experimental studies.

# Literature search and extraction strategy

The PubMed, Web of Science, Medline, Embase, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wanfang Database (WANFANG) were searched from their respective inception to June 1, 2023. The retrieval keywords were "multiple myeloma", "vitamin D receptor", and "polymorphism". The retrieval strategy is provided in Supplementary file 2. Two reviewers independently screened and extracted the data. If there were any discrepancies, a third individual reviewed the articles. The data extracted included the following: first author, publication data, sample source, ethnicity, genotyping method, sample size, and genotype characterization for the cases and controls.

#### Quality evaluation of the included studies

The quality of the studies included in this meta-analysis was evaluated using the Newcastle–Ottawa Scale (NOS) [27]. The full score was 9, and high quality was defined as a study with  $\geq$  7.

### **Statistical analysis**

The data for the meta-analysis and sensitivity analysis were analyzed using Comprehensive Meta-Analysis (CMA, version 3.0). The trim-and-fill method was used to test publication bias using STATA 12.0 (STATA Corporation, Texas, USA). According to whether the heterogeneity was low ( $I^2 < 50$ ), or high ( $I^2 \ge 50\%$ ), we used fixed- or randomeffects models, respectively. The OR was used as a summary statistic for dichotomous variables. The 95% CI was calculated for all mean values. *P* values > 0.05 were considered not significant.

To explore the source of heterogeneity among the studies included in the review, a leave-one-out sensitivity analysis in which a meta-analysis was conducted on each subset of the studies obtained by leaving out exactly one study, was performed.Publication bias was tested using Begg's and Egger's tests. If P < 0.05, publication bias existed, and the trim-and-fill method was used to identify and correct for publication bias.

# Results

## Characteristics of the included studies

A total of 38 references were identified in the initial examination. After layer-by-layer screening, six case-control studies were included in this analysis. Four case-control studies with 342 cases and 336 controls were included for TaqI (rs731236), four case-control studies with 689 cases and 1222 controls were included for ApaI (rs7975232), four case-control studies with 689 cases and 1147 controls included for BsmI (rs1544410), and six case-control studies with 877 cases and 1414 controls were included for FokI (rs2228570). The flow of the literature screening is detailed in Fig. 1. The included studies involved individuals of Asian ethnicity, four studies included individuals of Chinese Han ethnicity, one study included individuals of Indian ethnicity, and one study included individuals of Kashmiri ethnicity. PCR was the main genotyping method employed. The results of the quality assessment of the literature showed that the scores of the included studies ranged from ranged from 7 to 8 points, indicating that the studies were rated good or better. The basic characteristics of the included studies and the results of the quality evaluation are shown in Table 1. All genotype frequencies of the control group were consistent with the HWE. The genotype data are provided in Supplementary file 3.


## Meta-analysis results

## Association between Taql (rs731236) and MM risk

A total of 342 patients and 336 controls were included in the analysis. A summary of the heterogeneity analysis, meta-analysis results, and publication bias assessment is shown in Table 2. No heterogeneity was observed in the allelic model (C vs. T,  $I^2 = 46.811\%$ , P = 0.130) and dominant model (CC + CT vs. TT,  $I^2 = 0.000\%$ , P = 0.478), recessive model (CC vs. TT + CT,  $I^2 = 30.667\%$ , P = 0.236), and homozygote model (CC vs. TT,  $I^2 = 0.000\%$ , P = 0.380), and high heterogeneity existed in the heterozygous model (CT vs. TT,  $I^2 = 91.613\%$ , P = 0.000). The results from the metaanalysis showed that TaqI (rs731236) was associated with MM risk in the allelic model (OR 1.487, 95% CI 1.052, 2.104, P=0.025; Fig. 2a) and dominant model (OR 1.830, 95% CI 1.138, 2.944; P = 0.013; Fig. 2d). The results of Begg's and Egger's tests showed no publication bias for the allelic model (Egger's test: P = 0.141, Begg's test: P = 0.174) and dominant model (Egger's test: P = 0.205, Begg's test: P = 0.174).

According to the primary meta-analysis results, the presence of TaqI (rs731236) was found to be independent of MM in the homozygote model (OR 1.680, 95% CI 0.556, 5.076; P=0.358; Fig. 2b), heterozygous model (OR 0.455, 95% CI 0.061, 3.394; P=0.442; Fig. 2c), and recessive model (OR 0.942, 95% CI 0.508, 1.746; P=0.850; Fig. 2e). However, publication bias was found for the recessive model (Egger's test: P=0.012, Begg's test: P=0.117), the homozygote model (Egger's test: P=0.012, Begg's test: P=0.117), and the heterozygous model (Egger's test: P=0.016, Begg's test: P=0.174). In heterozygous model, heterogeneity decreased (I<sup>2</sup>=46.781%, P=0.153) following the removal of the data from Raman Kumar [22] from the analysis, and

**Fig. 1** Flowchart of the literature-screening process



publication bias disappeared (Egger's test: P = 0.059, Begg's test: P = 0.296). Additionally, thetrim-and-fill method was applied to test the possible effect of publication bias, and the results are shown in Table 3. The results tended to be unchanged after adjusting for publication bias using the trim-and-fill method in the homozygote model (OR 0.934, 95% CI 0.232, 3.764; P = 0.924; Fig. 2f) and recessive model (OR 0.821, 95% CI 0.312, 2.164; P = 0.691; Fig. 2g).

#### Association between Apal (rs7975232) and MM risk

A total of 689 cases and 1222 controls were included in the analysis, and publication bias did not exist in any of the genetic model. A summary of the heterogeneity analysis, meta-analysis results, and publication bias assessment is shown in Table 4. Significant heterogeneity existed in the allelic model (T vs. G, I<sup>2</sup>=71.414%, P=0.015), homozygote model (TT vs. GG, I<sup>2</sup>=71.520%, P=0.015), dominant models (TT+TG vs. GG, I<sup>2</sup>=63.766%, P=0.041), heterozygous model (TG vs. GG, I<sup>2</sup>=56.475%, P=0.075), and recessive model (TT vs. GG+GT,  $I^2 = 65.229\%$ , P = 0.043). The primary meta-analysis results showed that ApaI is not associated with MM risk in the allelic model (OR 1.101, 95% CI 0.771, 1.572; P=0.598; Fig. 3a), homozygote model (OR 1.009, 95% CI 0.457, 2.226; P=0.983; Fig. 3b), heterozygous model (OR 1.226, 95% CI 0.996, 1.510; P=0.055; Fig. 3c), dominant model (OR 1.224, 95% CI 0.774, 1.936; P = 0.387; Fig. 3d), recessive model (OR 0.941, 95% CI 0.498, 1.779; P = 0.851; Fig. 3e). We further searched for sources of heterogeneity by conducting a sensitivity analysis, which was carried out by removing studies one by one. Heterogeneity was reduced after the elimination of the data from Syed Shafia [24], and statistical significance was obtained for the allelic model (OR 1.292, 95% CI 1.101, 1.517; P=0.002), dominant model (OR 1.353, 95% CI 1.103, 1.662; *P*=0.004), heterozygous model (OR 1.305, 95% CI 1.050, 1.622; *P* = 0.016), and homozygote model (OR 1.600, 95% CI 1.106, 2.314; P = 0.013). The heterogeneity in the recessive model decreased to 26.291% after excluding the study of Syed Shafia, and the results of the

References	Ethnicity	Genotyping method	Sample size (case/ control)	Sample source	NOS score
FokI(rs2228570)					
Rui et al. [23]	Chinese Han population	PCR	40/84	Elbow vein blood	7
Ni [21]	Chinese Han population	PCR	114/60	Venous blood	8
Chen et al. [20]	Chinese Han population	PCR-RFLP	460/928	Blood	8
He et al. [19]	Chinese Han population	PCR	113/117	Venous blood	8
Kumar et al. [22]	Indian population	PCR-RFLP	75/75	Bone marrow Blood	7
Shafia et al. [24]	Kashmiri population	PCR	75/150	Peripheral blood	8
ApaI (rs7975232)					
Rui et al. [23]	Chinese Han population	PCR	40/84	Elbow vein blood	7
Ni [21]	Chinese Han population	PCR	114/60	Venous blood	8
Chen et al. [20]	Chinese Han population	PCR-RFLP	460/928	Blood	8
Shafia et al. [24]	Kashmiri population	PCR	75/150	Peripheral blood	8
BsmI (rs1544410)					
Rui et al. [23]	Chinese Han population	PCR	40/84	Elbow vein blood	7
Ni [21]	Chinese Han population	PCR	114/60	Venous blood	8
Chen et al. [20]	Chinese Han population	PCR-RFLP	460/928	Blood	8
Kumar et al. [22]	Indian population	PCR-RFLP	75/75	Bone marrow blood	7
TaqI (rs731236)					
Rui et al. [23]	Chinese Han population	PCR	40/84	Elbow vein blood	7
Ni [21]	Chinese Han population	PCR	114/60	Venous blood	8
He et al. [19]	Chinese Han population	PCR	113/117	Venous blood	8
Kumar et al. [22]	Indian population	PCR-RFLP	75/75	Bone marrow blood	7

NOS Newcastle-Ottawa Scale, PCR polymerase chain reaction, PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism

Table 2         Meta-analysis of the association between multiple myeloma risk and the	Genetic model	del Test of association			Test of l geneity	netero-	Test of publication bias		
TaqI(rs731236)		OR	95% CI	Р	$\overline{I^2}$	Р	Egger's test (P)	Begg's test (P)	
	C versus T	1.487	1.052, 2.104	0.025	46.811	0.130	0.141	0.174	
	CC versus TT	1.680	0.556, 5.076	0.358	0.000	0.380	0.012	0.117	
	CT versus TT	0.455	0.061, 3.394	0.442	91.613	0.000	0.016	0.174	
	CC+CT versus TT	1.830	1.138, 2.944	0.013	0.000	0.478	0.205	0.174	
	$\frac{CC}{CC}$ versus $TT + CT$	0.942	0.508, 1.746	0.850	30.667	0.236	0.012	0.117	

meta-analysis remained statistically insignificant (OR 1.411, 95% CI 0.988, 2.017; P = 0.058). The results are shown in Table 5.

## Association between Bsml (rs1544410) and MM risk

Six hundred eighty-nine patients with MM and 1147 healthy control subjects were included. A summary of the heterogeneity results, meta-analysis results, and publication bias assessment is shown in Table 6. The results of Begg's and Egger's tests showed no publication bias. Heterogeneity tests revealed significant heterogeneity in the allelic model (G vs. A,  $I^2 = 75.272\%$ , P = 0.007) and recessive model (GG vs. AA + GA,  $I^2 = 74.332\%$ , P = 0.009). Primary meta-analysis results showed that the allelic model (OR 1.131, 95% CI 0.632, 2.023; P = 0.679; Fig. 4a) and recessive model (OR 1.158, 95% CI 0.506, 2.653; P = 0.728; Fig. 4e) were independent of MM risk. But heterogeneity was high, so




Fig.2 Forest plot of the association between TaqI(rs731236) and multiple myeloma for the allelic model (a), homozygote model (b), heterozygous model (c), dominant model (d), and recessive model (e). The adjusted funnel plot of the association between TaqI

 
 Table 3
 Trim-and-fill analysis of the eligible studies for the metaanalysis of the association between multiple myeloma risk and TaqI (rs731236)

Genetic model	Test of	association	Test of erogene		
	OR	95% CI	Р	Q	Р
CC versus TT	0.934	0.232, 3.764	0.924	5.947	0.203
CC versus TT + TC	0.821	0.312, 2.164	0.691	6.142	0.189

sensitivity analysis was carried out by removing trials one by one. Removal of the data from Ni Zhai [21] reduced the heterogeneity of allelic model and dominant model to zero, and the results of meta-analysis became statistically

(rs731236) and multiple myeloma after adjustment by the trim-andfill method for the homozygote model (**f**) and recessive model (**g**). The blank circles represent the original studies, whereas the blanked squares represent the imputed studies

significant (allelic model: OR 1.398, 95% CI 1.180, 1.657, P = 0.000; recessive model: OR 1.686, 95% CI 1.174, 2.423; P = 0.005), as shown in Table 7.

There was no obvious heterogeneity in the homozygote model (GG vs. AA,  $I^{2}=14.454\%$ , P=0.320), heterozygous model (GA vs. AA,  $I^{2}=32.359\%$ , P=0.218), and dominant model (GG+GA vs. AA,  $I^{2}=41.331\%$ , P=0.164), so the fixed-effect model was selected. The meta-analysis indicated a highly significant association between BsmI and the risk of MM for the homozygote model (OR 1.918, 95% CI 1.293, 2.844; P=0.001; Fig. 4b) and heterozygous model (OR 1.333, 95% CI 1.058, 1.679; P=0.015; Fig. 4c), but there was no association between BsmI and MM in dominant model (OR 1.554, 95% CI 0.827, 2.922; P=0.171; Fig. 4d).

Table 4 Meta-analysis of the association between multiple myeloma risk and the ApaI (rs7975232)

Genetic model	Test of association		Test of hetero- geneity		Test of publication bias		
	OR	95% CI	Р	$\overline{I^2}$	Р	Egger's test (P)	Begg's test (P)
T versus G	1.101	0.771, 1.572	0.598	71.414	0.015	0.691	1.000
TT versus GG	1.009	0.457, 2.226	0.983	71.520	0.015	0.483	1.000
TG versus GG	1.226	0.996, 1.510	0.055	56.475	0.075	0.797	0.496
TT+TG versus GG	1.224	0.774, 1.936	0.387	63.766	0.041	0.921	0.496
TT versus GG+TG	0.941	0.498, 1.779	0.851	65.229	0.043	0.406	1.000

Fig. 3 Forest plot for the association between ApaI (rs7975232) and multiple myeloma for the allelic model (**a**), homozygote model (b), heterozygous model (c), dominant model (d), and recessive model (e)

а	Study name Subgroup within stu	Odds ratio (95% CI) with study removed	
		Lower Upper Point limit limit Z-Value p-Value	
	Hongbing RuiT vs G	1.013 0.655 1.566 0.058 0.954	1 1 🗰 1 1
	Ni Zhai T vs G	1.076 0.665 1.739 0.298 0.765	
	Peng Chen T vs G	1.031 0.609 1.744 0.113 0.910	
	Syed Shafia T vs G	1.292 1.101 1.517 3.144 0.002	
		1.101 0.771 1.572 0.527 0.598	
			0.01 0.1 1 10 100
h			
D	Study name Subgroup within stud	ly Statistics for each study	Odds ratio and 95% Cl
		Odds Lower Upper ratio limit limit Z-Value p-Value	
	Hongbing RuiTT vs GG	1.750 0.449 6.825 0.806 0.420	
	Ni Zhai TT vs GG	0.849 0.288 2.502 -0.298 0.766	
	Peng Chen TT vs GG	1.738 1.154 2.619 2.644 0.008	
	Syed Shafia TT vs GG	0.404 0.178 0.915 -2.172 0.030	
		1.009 0.457 2.226 0.021 0.983	
			0.01 0.1 1 10 100
С			
Ŭ	Study name Subgroup within stud	·	Odds ratio and 95% CI
		Odds Lower Upper ratio limit limit Z-Value p-Value	
	Hongbing RuiTG vs GG	2.265 0.981 5.226 1.916 0.055	
	Ni Zhai TG vs GG	1.841 0.929 3.649 1.749 0.080	
	Peng Chen TG vs GG	1.197 0.943 1.519 1.474 0.140	
	Syed Shafia TG vs GG	0.621 0.302 1.276 -1.296 0.195 1.226 0.996 1.510 1.921 0.055	
		1.226 0.996 1.510 1.921 0.055	
_			0.01 0.1 1 10 100
a	Study name Subgroup within stud	ly Statistics for each study	Odds ratio and 95% CI
		Odds Lower Upper	
		ratio limit limit Z-Value p-Value	
	Hongbing RuiTT+TG vs GG	2.167 0.967 4.855 1.879 0.060	
	Ni Zhai TT+TG vs GG	1.574 0.834 2.969 1.400 0.161	
	Peng Chen TT+TG vs GG	1.281 1.023 1.604 2.162 0.031	
	Syed Shafia TT+TG vs GG	0.534 0.269 1.058 -1.799 0.072 1.224 0.774 1.936 0.865 0.387	
		1.224 0.774 1.930 0.803 0.387	
-			0.01 0.1 1 10 100
e	Study name Subgroup within stu	dy Statistics with study removed	Odds ratio (95% CI) with study removed
		Lower Upper	
		Point limit limit Z-Value p-Value	
	Hongbing RuiTT vs GG+GT	0.896 0.409 1.962 -0.275 0.783	
	Ni Zhai TT vs GG+GT	1.025 0.476 2.208 0.063 0.950	
	Peng Chen TT vs GG+GT	0.651 0.395 1.074 -1.681 0.093	
	Syed Shafia TT vs GG+GT	1.270 0.749 2.152 0.888 0.374	
		0.941 0.498 1.779 -0.188 0.851	$    \lor    $
			0.01 0.1 1 10 100

Favours A

Page 7 of 13 118

🖄 Springer

Favours B

Table 5Meta-analysis of theassociation between multiplemyeloma risk and the ApaI(rs7975232) after the removalof the study by Syed Shafia

Genetic model	Test of association		Test of hetero- geneity		Test of publication bias		
	OR	95% CI	Р	$\mathbf{I}^2$	Р	Egger's test (P)	Begg's test (P)
T versus G	1.292	1.101, 1.517	0.002	0.000	0.791	0.757	0.601
TT versus GG	1.600	1.106, 2.314	0.013	0.000	0.473	0.587	0.601
TG versus GG	1.305	1.050, 1.622	0.016	36.516	0.207	0.290	0.518
TT+TG versus GG	1.353	1.103, 1.662	0.004	0.000	0.416	0.783	0.117
TT versus GG+TG	1.411	0.988, 2.017	0.058	26.291	0.258	0.363	0.601

Table 6Meta-analysis of theassociation between multiplemyeloma risk and BsmI(rs1544410)

Genetic model	Test of association		Test of hetero- geneity		Test of publication bias		
	OR	95% CI	Р	$\mathbf{I}^2$	Р	Egger's test (P)	Begg's test (P)
G versus A	1.131	0.632, 2.023	0.679	75.272	0.007	0.688	1.000
GG versus AA	1.918	1.293, 2.844	0.001	14.454	0.320	0.470	0.496
GA versus AA	1.333	1.058, 1.679	0.015	32.359	0.218	0.749	1.000
GG+GA versus AA	1.554	0.827, 2.922	0.171	41.331	0.164	0.605	0.496
GG versus AA+GA	1.158	0.506, 2.653	0.728	74.332	0.009	0.928	1.000

#### Association between Fokl(rs2228570) and MM risk

There were 877 patients with MM and 1414 healthy controls involved in the study. A summary of the heterogeneity analysis, meta-analysis results, and publication bias assessment is shown in Table 8. No substantial heterogeneity existed in the allelic model (T vs. C,  $I^2 = 0.000\%$ , P = 0.458), dominant models (TT+CT vs. CC,  $I^2 = 0.000\%$ , P = 0.703), recessive model (TT vs. CC+CT,  $I^2 = 0.000\%$ , P = 0.710), homozygote model (TT vs. CC,  $I^2 = 0.000\%$ , P = 0.739), and heterozygous model (CT vs. CC,  $I^2 = 0.000\%$ , P = 0.668), and the test for publication bias was not significant. Meta-analysis found that FokI is associated with MM risk in the allelic model (OR 1.687, 95% CI 1.474, 1.931; P = 0.000; Fig. 5a), homozygote model (OR 2.829, 95% CI 2.066, 3.872; P=0.000; Fig. 5b), heterozygous model (OR 1.579, 95% CI 1.304, 1.913; P=0.000; Fig. 5c), dominant model (OR 1.771, 95%) CI 1.477, 2.125; P = 0.000; Fig. 5d), and recessive model (OR 2.409, 95% CI 1.814, 3.200; P=0.000; Fig. 5e).

## Discussion

Low level of vitamin D is related to increased risk of several cancers [28]. Vitamin D regulates the process of oncogenesis through immunomodulation, antioxidant defense, and DNA damage repair, which affects cancel cell proliferation and apoptosis [29]. Previous studies have investigated the relationship between VDR gene polymorphisms and MM [19–24]. However, the results of different studies are controversial. We therefore performed this meta-analysis to comprehensively evaluate these inconclusive findings.

TaqI (rs731236) is located at codon 352 in exon 9 of VDR gene, which creates a TaqI restriction site and related to transcriptional activity, mRNA stability, and the serum level of  $1,25(OH)_2D_3$  [30, 31]. Previous studies have reported that MM patients have a significantly greater frequency of the C allele at the TaqI than healthy controls [19, 23], but other studies have reached inconsistent conclusions [21, 22]. We included 342 patients and 336 controls from four studies. The results from this meta-analysis showed that TaqI is associated with MM in the dominant model and heterozygous model but is independent of MM risk in the allelic model, homozygote model, and recessive model.

ApaI (rs7975232) is positioned in intron 8 near the 3' end of VDR gene and has the potential to affect alternative splicing of the VDR mRNA [32]. Four studies did not support the association between ApaI and MM risk [20, 21, 23, 24], but one study reached the opposite conclusion [22]. In this meta-analysis, 689 patients and 1222 controls were included. There was heterogeneity in the primary analysis, and the heterogeneity disappeared after the elimination of the study from Syed Shafia [24]. Syed Shafia's study including individuals of Kashmiri ethnicity, while the subjects of the remaining four study subjects were of the Chinese Han ethnicity, which suggests that ethnicity might be the source of the heterogeneity. The meta-analysis results showed that **Fig. 4** Forest plots of the association of BsmI (rs1544410) and multiple myeloma for the allelic model (**a**), homozygote model (**b**), heterozygous model (**c**), dominant model (**d**), and recessive model (**e**)

Image:	а	Study name	Subgroup with	in study	Statistics for	r each stu	dy		Odds rat	io and 95% Cl	
Indeping Rul G vs A Nick Mumar G vs A Nick				Odds	Lower Uppe	er	_				
Nižni rodova do sola       0.223 0.077 0.650 - 2751 0.006 0.1006 0.100 0.006 0.100 0.006 0.0							-				
Ping Chen, G. vis, A       1352       1224       1626       3196       0.01         131       0.652       2.023       0.041       0.01       0											
Raman Kumar G vs A       1 20 1 027 2 55 2 074 0.033       0.01 0.01 0.01 0.000         B       Lini 0.632 2.023 0.414 0.67       Favours A       Favours A         B       Sudvame Subgroup withinstop       Statisto for each state       God ratio and 95% C         Mogbing Rui G vs AA       1.633 0.007 4.131 0.254 0.708       0.00       0											
1.131 0.832 2.023 0.414 0.67       0.1       1       1       0         0       0.1       1       1       0         0       Norman Nutran N		0									
b       Source       Source       Source       Source         M       Max mining and maximum and										$\langle \overline{2}  $	
b Sudy name Subgroup within study Def Linger (Su vs As 1 553 005741 431 0.254 0.059) Def Subs As 1 553 005741 431 0.254 0.059 Def Subs As 1 555 0057 0.056 0.057 Def Subs As 1 555 0057 0.051 0.051 Def Subs As 1 555 0057 0.051 0.050 Def Subs As 1 555 0057 0.050 0.050 Def Subs As 1 555 0057 0.050 0.050 Def Subs As 2 555 0.2452 0.051 Def Subs As 2 555 0.057 0.050 Def Subs As 2 555 0.057 0.050 Def Subs As 2 555 0.057 0.050 Def Subs As 2 550 0.050 0.050 0.050 0.050 Def Subs As 2 550 0.050 0.050 0.050 0.050 Def Subs As 2 550 0.057 0.050 Def Su								0.01	0.1	1 10	100
b Sudy name Subgroup within study Def Lingping Rui GG vs AA 1053 0007 11 131 0254 0.079 1070 1272 000 0280 0.000 1071 1230 0.041 0.000 0.000 1071 1230 0.041 0.000 1071 1230 0.000 0.000 1071 1230 0											
$ \begin{array}{c} \mathbf{C} \\ \mathbf{Study name} \\$	h								Favours A	Favours B	
ratio limit initi Z-value p-ValueHongbing Rui GG vs AA1.5330.057 41.4310.2540.769Ni ZhaiGG vs AA1.8981.2172.9602.8280.0501.911.2932.8443.2400.0510.010.010.010.010.110CStudy name Subgroup within studyStudy name Subgroup within studyOdds cover Upper ratioNi ZhaiGA vs AA0.4340.0209.3400.5330.554Ni ZhaiGA vs AA1.2650.9931.6111.9040.057Ni ZhaiGA vs AA1.2650.9931.6111.9040.011.3331.0581.6792.4380.0150.010.01Odds ratio and 95% CIOdds ratio and 95% CIOdds cover Upper raman KumarGA vs AA1.1450.0430.0410.9301.3331.0581.6792.4380.0150.010.010.01Odds ratio and 95% CIOdds ratio and 95% CI	D	Study name	Subgroup with	in study	Statistics for	each stud	dy		Odds rati	io and 95% Cl	
Nixing Peng Chen Raman KumarGG vs AA Raman KumarGG vs AA (148)0.145 1.898 1.217 2.960 2.628 0.6722 0.							p-Value				
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c}$		Hongbing Rui	GG vs AA	1.533	0.057 41.43	0.254	0.799			+	-
Raman KumarGG vs AA2.648 2.918 1.918 1.293 2.924 2.923 2.844 3.240 0.01Image and the state				0.145	0.008 2.66	9 -1.300	0.194	K-		<u>+</u>	
1.918       1.293       2.844       3.240       0.01       0.1       1       1       10         C       Study nam       Subgroup within study       Statistics for each study       Favours A       C       Odds ratio and 95% CI         C       Study nam       Subgroup within study       Statistics for each study       Odds       Odds ratio and 95% CI         C       Study nam       Subgroup within study       Statistics for each study       Odds       Odds ratio and 95% CI         C       Study nam       Subgroup within study       Statistics for each study       Odds       Statistics for each study       Stat		•		1.898	1.217 2.96	0 2.828	0.005				
C       Study nam< Subgroup within study		Raman Kuma	rGG vs AA								
C       Source N       Source N       Source N       Source N       Source N         State N				1.918	1.293 2.84	4 3.240	0.001	I	I	$ \diamond\rangle$	I
CStatistic for each studyOdds Lower Upper TatioIniti Z. Value p-Value Ni Zhai G Av S AAOdd A 000 0.013 12 636 0.512 0.603 0.023 10.013 12 636 0.512 0.603 0.033 1.059 1.679 2.438 0.015Odds atom 0.95% OdMorphing Rui GA vs AA 2.866 1.252 6.558 2.492 0.013 1.333 1.058 1.679 2.438 0.015Image def atom 0.936 0.533 0.594 0.001 1.094 0.053 0.594 0.001 1.094 0.013 12.636 0.512 0.603 0.001 0.001 1.094 0.053 0.594 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001Image def atom 0.001								0.01	0.1	1 10	100
$ \begin{array}{c} \mathbf{C} \\ \begin{array}{c} \mathbf{C} \\ C$	0								Favours A	Favours B	
$ \begin{array}{c} ratio \\ limit $	C	Study name	Subgroup with	in study	Statistics for	reach stud	dy		Odds rat	io and 95% Cl	
Hongbing Rui GA vs AA NiZhai GA vs AA0.407 0.403 0.403 0.403 0.200 9.840 0.403 0.200 9.840 0.503 0.653 0.658 0.409 0.409 0.409 0.400 0.401 0.401 0.401 0.401 0.402 0.401 0.402 0.401<							p-Value				
$ \begin{array}{c} \text{Ni} \vec{Z} \text{hai} & \text{GA} \text{ vs } AA \\ \text{Peng Chen} & \text{GA} \text{ vs } AA \\ \text{Peng Chen} & \vec{GA} \text{ vs } AA \\ 1.265 & 0.993 & 1.611 & 1.904 & 0.057 \\ 2.866 & 1.252 & 6.558 & 2.492 & 0.013 \\ 1.333 & 1.058 & 1.679 & 2.438 & 0.015 \\ \hline & \textbf{O} & \textbf$		Honabina Rui	GA vs AA				-	I.—		_ <b>_</b>	I.
$\begin{array}{c c c c c c c c c c c c c c c c c c c $											
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Peng Chen	GA vs AA	1.265	0.993 1.61	1 1.904	0.057				
e Marka Subgroup within study Statistics for each study Marka Subgroup within study Statistics for each study Marka Subgroup within study Odds Lower Upper Tatio Imiti Imiti Z-Value p-Value Modes Lower Upper Tatio Initi Imiti Z-Value p-Value More Ge Area A 1145 0.044 30.043 0.081 0.935 Ni Zhai GG+GA vs AA 1145 0.044 30.043 0.081 0.935 Ni Zhai GG+GA vs AA 1145 0.044 30.043 0.081 0.935 Ni Zhai GG+GA vs AA 1145 0.044 30.043 0.081 0.935 Ni Zhai GG+GA vs AA 11355 1.079 1.701 2.614 0.009 Raman KumarGG+GA vs AA 2.786 1.278 6.072 2.577 0.010 1.554 0.827 2.922 1.369 0.171 e e Marka Subgroup within study Statistics for each study Marka GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.328 0.720 14.572 1.531 0.126 Ni Zhai GG vs AA+GA 2.314 0.638 2.718 0.738 0.616 1.156 0.566 2.655 0.377 0.728		Raman Kuma	rGA vs AA								
d <u>Market Market Marke</u>				1.333	1.058 1.67	9 2.438	0.015			$\Diamond$	
Image: Subgroup within studyStatistics for each studyOdds a current of the study								0.01	0.1	1 10	100
Odds Lower Upper ratio       Iimit       Iimit       Iimit       Value p-Value         Hongbing Rui       GG+GA vs AA       1.145       0.044 30.043       0.081       0.935         Peng Chen       GG+GA vs AA       1.145       0.168       0.009       3.096       -1.200       0.230         Peng Chen       GG+GA vs AA       1.355       1.079       1.701       2.614       0.009         1.554       0.827       2.922       1.369       0.171       0.1       1       10         Favours A       Favours B       Odds       Codes Lower Upper       Tatio       Iimit       Iimit       Iimit       Codes Lower Upper       Odds ratio and 95% CI         Hongbing Rui       GG vs AA+GA       3.238       0.720 14.572       1.531       0.126       0.11       1       0         Ni Zhai       GG vs AA+GA       0.246       0.081       0.744       -2.483       0.013       0.1       1       0         Peng Chen       GG vs AA+GA       1.746       1.302       6.99       2.509       0.012       0.1       1       0         Ni Zhai       GG vs AA+GA       1.746       1.302       6.99       2.509       0.012       0.1       0.1       1	٩								Favours A	Favours B	
ratio       limit       limit <td< td=""><td>a</td><td>Study name</td><td>Subgroup with</td><td>in study</td><td>Statistics for</td><td>each stud</td><td>dy</td><td></td><td>Odds rati</td><td>io and 95% Cl</td><td></td></td<>	a	Study name	Subgroup with	in study	Statistics for	each stud	dy		Odds rati	io and 95% Cl	
Hongbing Rui GG+GA vs AA       1.145       0.044 30.043       0.081       0.935         Ni Zhai       GG+GA vs AA       0.168       0.009       3.096       1.200       0.230         Peng Chen       GG+GA vs AA       1.355       1.079       1.701       2.614       0.009         2.786       1.278       6.072       2.577       0.010       0.1       1       10         Favours A       Favours A       Favours B       Favours A       Favours B         C       Statistics for each study       Cdds       CddsCdds       Cdds       C							p-Value				
Ni Zhai       GG+GA vs AA       0.168       0.009       3.096       -1.200       0.230         Peng Chen       GG+GA vs AA       1.355       1.079       1.701       2.614       0.009         Raman KumarGG+GA vs AA       2.786       1.278       6.072       2.577       0.010         1.554       0.827       2.922       1.369       0.171       0.01       0.1       1       10         Favours A         Study name       Subgroup within study       Statistics for each study       0.01       0.1       1       10         Odds Lower Upper ratio       Imit       Imit       Imit       2.738       0.126       0.013       0.1       1       10         Ni Zhai       GG vs AA+GA       3.238       0.720 14.572       1.531       0.126       0.01       0.1       1       10         Ni Zhai       GG vs AA+GA       0.246       0.081       0.744       -2.483       0.013       1       10         Peng Chen       GG vs AA+GA       1.314       0.636       2.718       0.738       0.461       0.01       0.1       1       10          2.062       2.653		Honabina Rui	GG+GA vs AA	1 145				1	_		1
Raman KumarGG+GA vs AA       2.786       1.278       6.072       2.577       0.010         1.554       0.827       2.922       1.369       0.171       0.01       0.1       1       10         Favours A       Favours A         Odds Lower Upper ratio limit limit Z-Value p-Value         Hongbing Rui GG vs AA+GA       3.238       0.720 14.572       1.531       0.126         Ni Zhai       GG vs AA+GA       0.246       0.081       0.744       -2.483       0.012         Raman KumarGG vs AA+GA       1.314       0.636       2.718       0.738       0.461         1.158       0.506       2.653       0.347       0.728       0.01       0.1       1       10								←			
1.554       0.827       2.922       1.369       0.171       0.01       0.1       1       10         Favours A         Study name Subgroup within study       Statistics for each study         Odds Lower Upper ratio         Mi Zhai       GG vs AA+GA       3.238       0.720 14.572       1.531       0.126         Ni Zhai       GG vs AA+GA       3.238       0.720 14.572       1.531       0.126         Ni Zhai       GG vs AA+GA       1.314       0.636       2.718       0.01       0.1       1       10         Odds ratio and 95% CI		Peng Chen	GG+GA vs AA	1.355	1.079 1.70	1 2.614	0.009				
End       Cont		Raman Kuma	rGG+GA vs AA				0.010				
P       Statistics for each study       Odds ratio and 95% CI         Morgbing Rui GG vs AA+GA       0.246 0.081 0.744 - 2.483 0.013       0.1       1       10         Morgbing Chen GG vs AA+GA       1.314 0.636 2.653 0.347 0.728       0.01       0.1       1       10				1.554	0.827 2.92	2 1.369	0.171			$\Leftrightarrow$	
e <u>Study name</u> <u>Subgroup within study</u> <u>Statistics for each study</u> <u>Odds ratio and 95% CI</u> <u>Odds Lower Upper</u> ratio limit limit Z-Value p-Value Hongbing Rui GG vs AA+GA Ni Zhai GG vs AA+GA D246 0.081 0.744 -2.483 0.013 Peng Chen GG vs AA+GA 1.314 0.636 2.718 0.738 0.461 1.158 0.506 2.653 0.347 0.728 0.01 0.1 1 10								0.01	0.1	1 10	100
Odds Lower Upper ratio       Odds Lower Upper limit       Iimit       Iimit       Z-Value         Hongbing Rui GG vs AA+GA       3.238       0.720 14.572       1.531       0.126         Ni Zhai       GG vs AA+GA       0.246       0.081       0.744       -2.483       0.013         Peng Chen       GG vs AA+GA       1.746       1.130       2.699       2.509       0.012         Raman KumarGG vs AA+GA       1.314       0.636       2.718       0.738       0.461         1.158       0.506       2.653       0.347       0.728       0.01       0.1       1       10									Favours A	Favours B	
ratio limit limit Z-Value p-Value Hongbing Rui GG vs AA+GA Ni Zhai GG vs AA+GA Peng Chen GG vs AA+GA Raman KumarGG vs AA+GA 1.314 0.636 2.718 0.738 0.461 1.158 0.506 2.653 0.347 0.728 0.01 0.1 1 10	е	Study name	Subgroup with	in study	Statistics for	each stud	dy		Odds rat	io and 95% Cl	
Hongbing Rui GG vs AA+GA       3.238       0.720 14.572       1.531       0.126         Ni Zhai       GG vs AA+GA       0.246       0.081       0.744       -2.483       0.013         Peng Chen       GG vs AA+GA       1.746       1.130       2.699       2.509       0.012         Raman KumarGG vs AA+GA       1.314       0.636       2.718       0.728       0.461         0.01       0.1       1       10							n-Value				
Ni Zhai       GG vs AA+GA       0.246       0.081       0.744       -2.483       0.013         Peng Chen       GG vs AA+GA       1.746       1.130       2.699       2.509       0.012         Raman KumarGG vs AA+GA       1.314       0.636       2.718       0.738       0.461         1.158       0.506       2.653       0.347       0.728       0.01       0.1       1       10		Honghing Pui					-	I	1		I
Peng Chen         GG vs AA+GA         1.746         1.130         2.699         2.509         0.012           Raman KumarGG vs AA+GA         1.314         0.636         2.718         0.738         0.461           1.158         0.506         2.653         0.347         0.728         0.01         0.1         1         10									┼╼╌	_  =	
1.158       0.506       2.653       0.347       0.728                          0.01       0.1       1       10											
0.01 0.1 1 10		Raman Kuma	rGG vs AA+GA	1.314	0.636 2.71	8 0.738	0.461				
				1.158	0.506 2.65	0.347	0.728		-	$\diamond$	
Favours A Favours B								0.01	0.1	1 10	100
									Favours A	Favours B	
Genetic model Test of association Test of hetero- Test of publication bias	Genet	ic model	Test of	association		Test o	of heter	o- Te	est of public	ation bias	
geneity									r		
$\overline{OR}$ 95% CI P $\overline{I^2}$ P $\overline{Egger's test (P)}$ Begg's test			OR	95% CI	Р	$\overline{I^2}$	Р	– Eg	gger's test (l	P) Begg's tes	st (P)

Table 7Meta-analysis of the<br/>association between multiple<br/>myeloma risk and BsmI<br/>(rs1544410) polymorphism<br/>after the removal of the study<br/>by Ni Zhai

G versus A

GG versus AA+GA

1.398

1.686

1.180, 1.657

1.174, 2.423

0.000

0.005

0.000

0.000

0.582

0.549

0.113

0.723

🖄 Springer

0.117

0.601

Table 8Meta-analysis of theassociation between multiplemyeloma risk and FokI(rs2228570)

Genetic model	Test of association			Test of hetero- geneity		Test of publication bias	
	OR	95% CI	Р	$\overline{\mathbf{I}^2}$	Р	Egger's test (P)	Begg's test (P)
T versus C	1.687	1.474, 1.931	0.000	0.000	0.458	0.940	0.850
TT versus CC	2.829	2.066, 3.872	0.000	0.000	0.739	0.876	0.188
TC versus CC	1.579	1.304, 1.913	0.000	0.000	0.668	0.819	0.850
TT+TC versus CC	1.771	1.477, 2.125	0.000	0.000	0.703	0.947	0.573
TT versus CC+TC	2.409	1.814, 3.200	0.000	0.000	0.710	0.882	0.573

ApaI is correlated with MM risk in the allelic model, dominant model, and homozygote model.

Previous studies reported that BsmI (rs1544410) is located at the 3' end of the noncoding region of VDR gene, and enhances the stability and transcriptional activity of VDR gene [30]. Previous studies reported that BsmI is significantly associated with MM risk [21–23], but one study reported that there is no association [20]. This meta-analysis included 689 cases and 1147 healthy controls. Removing the data from Ni Zhai's study [21] reduced the heterogeneity in the allelic model and dominant model, and the meta-analysis indicated a highly significant association between BsmI and the risk of MM in the allelic model, recessive model, homozygote model and heterozygous model.

FokI (rs2228570) is located in exon 2 of VDR gene. The association between FokI polymorphism and increased MM risk was described in four studies [19, 20, 22, 24], whereas opposite results were reported in the other two studies [21, 23]. In this meta-analysis, we pooled data of 877 MM patients and 1414 healthy controls from six studies. The meta-analysis revealed that FokI is associated with MM risk in the allelic model, dominant model, recessive model, homozygote model, and heterozygous model. Collectively, individuals with the T genotype had a significantly greater risk of MM than those with the C genotype. Previous studies

have reported that the C to T conversion causes shortening of the generated proteins by three amino acids and the loss of the FokI-recognition site, causing the VDR to be less effective as a transcriptional activator and resulting in a lower vitamin D status, thus, decreasing the anti-cancer effects of vitamin D [33].

In this study, a meta-analysis to evaluate the polymorphisms of VDR gene (FokI, BsmI and ApaI) and MM risk was performed for the first time, and TaqI, FokI, ApaI, and BsmI polymorphisms were found to be associated with MM risk. However, SNPs have geographical and ethnic differences; the results of this meta-analysis may be difficult to extrapolate to non-Asian populations because the included studies examining the association between VDR polymorphisms and MM were limited to Asian participants. The association between VDR gene polymorphisms and MM has not been widely studied, resulting in the relatively small number of included studies. Further highquality studies with multiple ethnicities and larger sample sizes are needed. Although a meta-analysis of VDR gene polymorphisms and MM risk provides valuable information, we must be cautious in how interpret these associations and continue to conduct in-depth research to reveal the potential underlying biological mechanism involved.

Fig. 5 Forest plots for the association between FokI (rs2228570) and multiple myeloma risk for the allelic model (**a**), homozygote model (**b**), heterozygous model (**c**), dominant model (**d**), and recessive model (**e**)

2			
а	Study name Subgroup within	study Statistics for each study	Odds ratio and 95% CI
		Odds Lower Upper	
		ratio limit limit Z-Value p-Value	
	Hongbing Rui T vs C	1.330 0.774 2.285 1.031 0.302	
	Ni Zhai T vs C	1.525 0.967 2.403 1.816 0.069	
	Peng Chen T vs C	1.670 1.390 2.005 5.486 0.000	
	Yanfang He T vs C	1.463 1.011 2.118 2.019 0.043	
	Raman KumarT vs C	1.980 1.142 3.431 2.435 0.015	
	Syed Shafia T vs C	2.385 1.593 3.571 4.222 0.000 1.687 1.474 1.931 7.591 0.000	
		1.007 1.474 1.951 7.591 0.000	
			0.01 0.1 1 10 100
_			
h			Favours A Favours B
D	Study name Subgroup within	study Statistics for each study	Odds ratio and 95% CI
	<u> </u>	Odds Lower Upper	
		ratio limit limit Z-Value p-Value	
	Hongbing Rui TT vs CC	2.308 0.712 7.483 1.393 0.164	
	Ni Zhai TT vs CC	2.424 0.941 6.243 1.834 0.067	
	Peng Chen TT vs CC	2.624 1.663 4.138 4.148 0.000	
	Yanfang He TT vs CC	2.407 1.075 5.393 2.135 0.033	
	Raman KumarTT vs CC	2.811 0.660 11.966 1.398 0.162	
	Syed Shafia TT vs CC	5.333 2.338 12.167 3.978 0.000	
		2.829 2.066 3.872 6.489 0.000	
			0.01 0.1 1 10 100
			Favours A Favours B
С			
•	Study name Subgroup within	study Statistics for each study	Odds ratio and 95% Cl
		Odds Lower Upper	
		ratio limit limit Z-Value p-Value	
	Hongbing Rui TC vs CC	0.953 0.411 2.213 -0.112 0.911	
	Ni Zhai TC vs CC	1.196 0.571 2.508 0.475 0.635	
	Peng Chen TC vs CC	1.656 1.303 2.104 4.122 0.000	
	Yanfang He TC vs CC	1.399 0.765 2.558 1.089 0.276	
	Raman KumarTC vs CC	2.249 1.117 4.528 2.269 0.023	
	Syed Shafia TC vs CC	1.590 0.746 3.390 1.200 0.230	
		1.579 1.304 1.913 4.668 0.000	
			0.01 0.1 1 10 100
			5
Ч			Favours A Favours B
u	Study name Subgroup within	study Statistics for each study	Odds ratio and 95% CI
		Odds Lower Upper	
		ratio limit limit Z-Value p-Value	
	Hongbing Rui TT+TC vs CC	1.154 0.519 2.563 0.351 0.725	
	Ni Zhai TT+TC vs CC	1.480 0.735 2.979 1.097 0.273	
	Peng Chen TT+TC vs CC	1.779 1.417 2.234 4.965 0.000	
	Yanfang He TT+TC vs CC	1.593 0.893 2.840 1.577 0.115	
	Raman KumarTT+TC vs CC	2.322 1.191 4.527 2.473 0.013	
	Syed Shafia TT+TC vs CC	2.471 1.219 5.006 2.510 0.012	
		1.771 1.477 2.125 6.157 0.000	
			0.01 0.1 1 10 100
			Favours A Favours B
$\mathbf{\Delta}$			
		study Statistics for each study	Odds ratio and 95% Cl
C	Study name Subgroup within		
C	Study name Subgroup within	Odds Lower Upper	
C		Odds Lower Upper ratio limit limit Z-Value p-Value	
C	Hongbing Rui TT vs CC+TC	Odds Lower Upper ratio limit limit Z-Value p-Value 2.375 0.820 6.879 1.594 0.111	
C	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066	
C	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001	
C	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066	
С	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC Raman KumarTT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311	
U	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311           3.907         2.076         7.353         4.224         0.000	
5	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC Raman KumarTT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311	
C	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC Raman KumarTT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311           3.907         2.076         7.353         4.224         0.000	
J	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC Raman KumarTT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311           3.907         2.076         7.353         4.224         0.000	0.01 0.1 1 10 100 Favours A Favours B
U	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC Raman KumarTT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311           3.907         2.076         7.353         4.224         0.000	
U	Hongbing Rui TT vs CC+TC Ni Zhai TT vs CC+TC Peng Chen TT vs CC+TC Yanfang He TT vs CC+TC Raman KumarTT vs CC+TC	Odds         Lower         Upper           ratio         limit         limit         Z-Value           2.375         0.820         6.879         1.594         0.111           2.164         0.950         4.931         1.837         0.066           2.174         1.392         3.395         3.414         0.001           1.932         0.959         3.893         1.842         0.066           2.087         0.502         8.675         1.012         0.311           3.907         2.076         7.353         4.224         0.000	

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10238-024-01382-4.

Acknowledgements Not applicable.

Author contributions R.X. and C.L. conceived the study. C.L. and T.W. contributed to the data acquisition and analyses. X.Y. and Z.L. helped to perform the data analyses. C.L. drafted the manuscript. R.X. helped in funding acquisition. All of the authors have reviewed and approved the final manuscript.

**Funding** This study was supported by the Natural Science Foundation of Shandong Province (No. ZR2020KH023).

**Data availability** Supporting data are available from the corresponding author on reasonable request.

## Declarations

Conflict of interest The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

# References

- Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-72. https://doi.org/10.1182/ blood-2007-10-078022.
- Ismail NH, Mussa A, Al-Khreisat MJ, Yusoff SM, Husin A, Johan MF, et al. The global prevalence of vitamin D deficiency and insufficiency in patients with multiple myeloma: a systematic review and meta-analysis. Nutrients. 2023. https://doi.org/ 10.3390/nu15143227.
- Mirhosseini N, Psihogios A, McLaren MD, Seely D. Vitamin D and multiple myeloma: a scoping review. Curr Oncol. 2023;30(3):3263–76. https://doi.org/10.3390/curroncol300302 48.
- Puthier D, Bataille R, Barille S, Mellerin M-P, Harousseau J-L, Ponzio A, et al. High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study. Support Care Cancer. 2021;30(1):271–8. https://doi.org/10.1007/s00520-021-06414-3.
- Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, et al. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer. 2016. https://doi.org/10.1007/s00520-016-3126-1.
- Yellapragada SV, Fillmore NR, Frolov A, Zhou Y, Dev P, Yameen H, et al. Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020;4(8):1643–6. https://doi.org/ 10.1182/bloodadvances.2019001411.

- Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol. 2000;109(3):576–83. https://doi.org/10. 1046/j.1365-2141.2000.02046.x.
- Park WH, Seol JG, Kim ES, Binderup L, Koeffler HP, Kim BK, et al. The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells. Int J Oncol. 2002;20(3):533–42.
- Puthier D, Bataille R, Barille S, Mellerin M-P, Harousseau J-L, Ponzio A, et al. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood. 1996;88(12):4659–66. https://doi.org/10.1182/blood. V88.12.4659.bloodjournal88124659.
- Park WH, Seol JG, Kim ES, Jung CW, Lee CC, Binderup L, et al. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp Cell Res. 2000;254(2):279–86. https://doi.org/10.1006/excr.1999.4735.
- Kumagai T, O'Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst. 2003;95(12):896–905. https://doi.org/10.1093/jnci/95.12.896.
- Cavalier E, Makris K, Heijboer AC, Herrmann M, Souberbiellee J-C. Vitamin D: analytical advances, clinical impact, and ongoing debates on health perspectives. Clin Chem. 2024. https://doi.org/ 10.1093/clinchem/hvae056.
- Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J. 2010;9(1):66. https://doi.org/10.1186/ 1475-2891-9-65.
- Bouillon R, Carmeliet G, Verlinden L, Etten Ev, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76. https://doi.org/10.1210/er.2008-0004.
- Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177(1–2):145–59. https://doi.org/10.1016/s0303-7207(01) 00406-3.
- Vaughan-Shaw PG, O'Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer. 2017;116(8):1092–110. https://doi.org/10.1038/bjc.2017.44.
- Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, et al. Risk factors for multiple myeloma: a systematic review of meta-analyses. Clin Lymphoma Myeloma Leuk. 2015;15(10):563-77.e773. https://doi.org/10.1016/j.clml. 2015.06.003.
- Gnagnarella P, Raimondi S, Aristarco V, Johansson H, Bellerba F, Corso F, et al. Ethnicity as modifier of risk for Vitamin D receptors polymorphisms: comprehensive meta-analysis of all cancer sites. Crit Rev Oncol Hematol. 2021;158: 103202. https://doi.org/ 10.1016/j.critrevonc.2020.103202.
- He Y, Ou C, Pang W, Lin Y, He J, Li C, et al. Genetic association of VDR polymorphisms and multiple myeloma susceptibility: a case control study. Int J Clin Exp Pathol. 2017;10(3):3538–42.
- Chen P, Du Z-L, Zhang Y, Liu B, Guo Z, Lou J-X, et al. Association of VEGF and VDR gene–gene and gene-smoking interaction on risk of multiple myeloma in Chinese Han population. Oncotarget. 2017;8(22):36509–16. https://doi.org/10.18632/oncotarget. 16510.
- Ni Z, Vitamin D. Receptor gene polymorphism and it's association with multiple myeloma. People's Hospital of Xinjiang Uygur Autonomous Region. Urumqi: Xinjiang Medical University; 2020.

- 22. Kumar R, Himani A, Gupta N, Singh V, Kumar V, Haq A, et al. Unveiling molecular associations of polymorphic variants of VDR gene (FokI, BsmI and ApaI) in multiple myeloma patients of Indian population. J Steroid Biochem Mol Biol. 2020. https:// doi.org/10.1016/j.jsbmb.2020.105588.
- Rui H, Liu Y, Lin M, Zheng X. Vitamin D receptor gene polymorphism is associated with multiple myeloma. J Cell Biochem. 2020;121(1):224–30. https://doi.org/10.1002/jcb.29135.
- Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis. 2013;51(1):56–60. https://doi.org/10.1016/j.bcmd.2013. 02.001.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.
- Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7(1):16. https:// doi.org/10.1186/1472-6947-7-16.
- 27. Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis; 2012. Accessed 2012.
- 28. Zhang R, Zhang Y, Liu Z, Pei Y, Xu P, Chong W, et al. Association betweeN vitamin D supplementation and cancer mortality: a systematic review and meta-analysis. Cancers. 2022;14(15):66. https://doi.org/10.3390/cancers14153717.

- Jeon S-M, Shin E-A. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):1–14. https://doi.org/10. 1038/s12276-018-0038-9.
- Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
- Martelli FS, Mengoni A, Martelli M, Rosati C, Fanti E. VDR TaqI polymorphism is associated with chronic periodontitis in Italian population. Arch Oral Biol. 2011;56(12):1494–8. https://doi.org/ 10.1016/j.archoralbio.2011.06.012.
- 32. Castillo-Avila RG, González-Castro TB, Tovilla-Zárate CA, Juárez-Rojop IE, López-Narváez ML, Rodríguez-Pérez JM, et al. The role of TaqI, ApaI and BsmI polymorphisms of VDR gene in lumbar spine pathologies: systematic review and meta-analysis. Eur Spine J. 2021;30(7):2049–59. https://doi.org/10.1007/ s00586-021-06872-7.
- 33. Cong L, Wang W, Liu Q, Du J. FokI polymorphism of the vitamin D receptor gene is associated with susceptibility to gastric cancer: a case–control study. Tohoku J Exp Med. 2015;236(3):219–24. https://doi.org/10.1620/tjem.236.219.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.